NCT06239727 2026-03-06
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Sun Yat-sen University
Phase 3 Recruiting
Clinical Trials
17 trialsNCT07432087 2026-02-25
Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT05198609 2026-01-21
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University
Phase 3 Active not recruiting
NCT05613478 2024-12-31
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT06086457 2024-07-16
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3 Recruiting
NCT06438627 2024-07-16
Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial
Sun Yat-sen University
Phase 3 Recruiting
NCT03427827 2024-04-09
DIPPER
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04674956 2024-04-02
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RenJi Hospital
Phase 3 Recruiting
NCT05798793 2024-04-02
NEOPCOSCC
Hospital of Stomatology, Wuhan University
Phase 3 Recruiting
NCT05999149 2024-02-21
BCTOP-T-N01
Fudan University
Phase 3 Recruiting
NCT05854849 2023-05-11
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
Sun Yat-sen University
Phase 3 Recruiting
NCT05772208 2023-03-16
Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy
Fudan University
Phase 3 Recruiting
NCT05610332 2022-11-09
Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
Fujian Medical University
Phase 3 Not yet recruiting
NCT05049681 2021-09-20
Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell
The First Affiliated Hospital of Zhengzhou University
Phase 3 Unknown
NCT04768075 2021-02-24
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
Guangdong Association of Clinical Trials
Phase 3 Unknown
NCT04453826 2020-09-28
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04404491 2020-05-27
Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence
The First Affiliated Hospital of Henan University of Science and Technology
Phase 3 Unknown